Blue Lake Biotechnology Inc, a clinical-stage intranasal vaccine company, on Monday reported the presentation of interim data from the company's Phase 1/2a paediatric clinical trial of RSV vaccine candidate BLB201 as a late-breaking abstract at the International Society for Vaccines 2026 Annual Congress in Antwerp, Belgium.
BLB201 is an intranasal RSV vaccine candidate being evaluated in Phase 1/2a clinical testing in children aged 8 to 59 months. It uses a proprietary PIV5 vector to express the RSV-F protein.
Interim data indicated that BLB201 may prevent symptomatic RSV infection in young children.
BLB201 has received Fast Track designation from the US Food and Drug Administration for prevention of RSV-associated acute respiratory disease in adults aged over 60 years and paediatric populations.
CelLBxHealth secures USD65,000 pharmaceutical research contract
Racura Oncology receives approval for RC220 trial to proceed to higher dose
Blue Lake Biotechnology reports interim data from Phase 1/2a paediatric clinical trial of BLB201
Solvonis signs Portugal agreement to assess European expansion of Phase 3 alcohol addiction trial
ABL Texcell Diagnostics acquires IntegraGen assets to expand into precision oncology
Akeso reports first patient dosed in Phase III study of cadonilimab in colon cancer
Natera secures FDA Breakthrough Device designation for multi-cancer early detection assay
FDA approves Genentech's Tecentriq combination therapy for stage III colon cancer
Alpheus Medical starts new clinical trial of PoMA therapy in butterfly glioblastoma
Sophos IRB and ALCMI partner to support lung cancer research
Northwest Biotherapeutics and NHSBT collaborate to support production of DCVax-L
argenx reports positive Phase 2 results for FB102 in coeliac disease